Diagnosis: Acute ischemic stroke caused by distal left internal carotid artery occlusion, with salvageable penumbral tissue and a persistent large-vessel occlusion. B.H. Buck is a Fellow of the ...

Ali, H. , Ghaysaa, H. , Jaafar, W. and Malek, M. (2025) Ischemic Stroke Following Coronary Angiography: A Case Report. Case ...

TIA is an acute ischemic event in the brain that typically resolves within two to 15 minutes, often leaving no detectable structural damage on imaging. While stroke is well recognized as a major ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Self-perceived stress among young women was significantly associated with increased risk for early-onset cryptogenic ischemic ...

The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...

Traumatic brain injury and acute ischemic stroke are major causes of mortality and morbidity throughout the world. Treatment in both conditions remains partially successful. In recent years ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

FRIDAY, Jan. 31, 2025 (HealthDay News) -- Dental flossing is associated with a lower risk for ischemic and cardioembolic stroke and atrial fibrillation (AF), according to a study presented at the ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to the manufacturer. Genentech said in a press release that TNKase ...

The AcT (Alteplase compared to Tenecteplase) trial compared TNKase to Activase in treating patients with acute ischemic stroke that presented with a disabling neurological deficit. This ...